title: Evaluation of pantoprazol treatment response of patients with asthma and gastroesophageal reflux: a randomized prospective double-blind placebo-controlled study.
abstract: OBJECTIVE
  To determine the effect that the treatment of GERD has on the clinical management, as well as the respiratory function, of patients with asthma and to evaluate the clinical characteristics of this group of patients.
  
  
  METHODS
  Patients with asthma and concomitant GERD, documented using 24 h pH-metry, were evaluated by means of quality of life questionnaires, as well as questionnaires related to respiratory and digestive symptoms. In addition, esophageal manometry, spirometry and the determination of peak expiratory flow were also performed prior to and after the study. Forty-nine individuals who were diagnosed with GERD by means of 24 h esophageal pH-metry were selected and participated in a clinical randomized double-blind placebo-controlled study, involving the administration of 40 mg/day of pantoprazol for 12 consecutive weeks.
  
  
  RESULTS
  Forty-four individuals completed the study (n = 22 per group). There was significant improvement in the scores for respiratory symptoms and quality of life only in the group that received pantoprazol (p = 0.01 and p = 0.001, respectively). No respiratory function parameters changed in either group.
  
  
  CONCLUSIONS
  In this study, the effective treatment of GERD improved patient quality of life, and the symptoms of asthma significantly decreased in the group that received the medication. There were no changes in pulmonary function parameters.
authors.affiliation: Federal University of Rio Grande do Sul, Porto Alegre, RS, Brasil.
authors.forename: Leandro Heusi
authors.initials: LH
authors.lastname: dos Santos
authors.forename: Iana Oliveira e Silva
authors.initials: IO
authors.lastname: Ribeiro
authors.forename: Pablo Gerardo
authors.initials: PG
authors.lastname: Sánchez
authors.forename: Jorge Lima
authors.initials: JL
authors.lastname: Hetzel
authors.forename: José Carlos
authors.initials: JC
authors.lastname: Felicetti
authors.forename: Paulo Francisco Guerreiro
authors.initials: PF
authors.lastname: Cardoso
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use*; D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology* / Q000628:therapy; D004812:Epidemiologic Methods; D004947:Esophagus / Q000503:physiopathology; D005260:Female; D005541:Forced Expiratory Volume; D005745:Gastric Acidity Determination; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008365:Manometry; D008499:Medical Records; D008875:Middle Aged; D000077402:Pantoprazole; D010366:Peak Expiratory Flow Rate; D010919:Placebos; D011788:Quality of Life; D012129:Respiratory Function Tests; D013147:Spirometry / Q000379:methods; D013997:Time Factors
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D010919:Placebos; D000077402:Pantoprazole